Nonclinical pharmacology and toxicology studies of LY01620, a therapeutic mRNA vaccine against human papillomavirus 16-related cancers
Abstract
Human papillomavirus (HPV) infection and related cancers remain significant public health concerns worldwide. Among high-risk HPV genotypes, HPV16 demonstrates the highest epidemiological prevalence. The viral oncoproteins E6 and E7 are crucial drivers of HPV16-associated carcinogenesis and have become key therapeutic targets for treating HPV16-related cervical intraepithelial neoplasia and cancers. HPV prophylactic vaccines have been widely implemented in clinical practice; however, effective therapeutic interventions for infected individuals remain limited. Therefore, the development of therapeutic HPV vaccines is urgently needed. LY01620 is an investigational mRNA therapeutic vaccine targeting HPV16 E6/E7 antigens. To support LY01620’s clinical trial application and development, comprehensive nonclinical studies were conducted, including immunogenicity evaluations in mice and rats, anti-tumor activity and mechanistic studies in C3.43 tumor-bearing mice, single-dose tissue distribution study in rats, and a GLP-compliant repeated-dose toxicity study in rats combined with toxicokinetics, local irritation, and immunotoxicity assessments. LY01620 demonstrated strong immunogenicity in mice and rats and exhibited significant anti-tumor activity through inducing a strong Th1-polarized immune response, increasing frequency of antigen-specific T cells, and enhancing infiltration of CD8+ T cells and mature macrophages into tumors. LY01620 mRNA exhibited sustained accumulation in inguinal lymph nodes and spleens, potentially facilitating persistent antigen presentation and prolonged immunological effects. In the repeated-dose toxicity study in SD rats, LY01620 exhibited a favorable safety profile, with the no observed adverse effect level was the highest dose of 300 μg/animal. In conclusion, preclinical studies have demonstrated that LY01620 exhibited favorable mechanism of action-related efficacy and a well-tolerated safety profile, supporting its further development.
Related
- Quadruple co-culture vascular models of haematological malignancy CAR T cell therapy for nonclinical safety and efficacy studies
- Alkaloidal constituents of Crinum asiaticum L., toxicology and in silico studies against some piercing-sucking pests
- Drug-centric knowledge graph: representing therapeutic modality, pharmacology and multiscale biology
- Editorial: Potential therapeutic targets in alcohol use disorder: insights from recent preclinical studies
- Network pharmacology-based investigation of the therapeutic effects and molecular mechanisms of oxymatrine in psoriasis
BibTeX
@article{du2026nonclinical,
title = {{Nonclinical pharmacology and toxicology studies of LY01620, a therapeutic mRNA vaccine against human papillomavirus 16-related cancers}},
author = {Guangying Du and Nouredine Behloul and Chunjie Sha and Wenzhong Chen and Jingwei Tian},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.1978903},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1978903},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Nonclinical pharmacology and toxicology studies of LY01620, a therapeutic mRNA vaccine against human papillomavirus 16-related cancers
AU - Guangying Du
AU - Nouredine Behloul
AU - Chunjie Sha
AU - Wenzhong Chen
AU - Jingwei Tian
PY - 2026
DA - 2026/11/04
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1978903
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1978903
AB - Human papillomavirus (HPV) infection and related cancers remain significant public health concerns worldwide. Among high-risk HPV genotypes, HPV16 demonstrates the highest epidemiological prevalence. The viral oncoproteins E6 and E7 are crucial drivers of HPV16-associated carcinogenesis and have become key therapeutic targets for treating HPV16-related cervical intraepithelial neoplasia and cancers. HPV prophylactic vaccines have been widely implemented in clinical practice; however, effective therapeutic interventions for infected individuals remain limited. Therefore, the development of therapeutic HPV vaccines is urgently needed. LY01620 is an investigational mRNA therapeutic vaccine targeting HPV16 E6/E7 antigens. To support LY01620’s clinical trial application and development, comprehensive nonclinical studies were conducted, including immunogenicity evaluations in mice and rats, anti-tumor activity and mechanistic studies in C3.43 tumor-bearing mice, single-dose tissue distribution study in rats, and a GLP-compliant repeated-dose toxicity study in rats combined with toxicokinetics, local irritation, and immunotoxicity assessments. LY01620 demonstrated strong immunogenicity in mice and rats and exhibited significant anti-tumor activity through inducing a strong Th1-polarized immune response, increasing frequency of antigen-specific T cells, and enhancing infiltration of CD8+ T cells and mature macrophages into tumors. LY01620 mRNA exhibited sustained accumulation in inguinal lymph nodes and spleens, potentially facilitating persistent antigen presentation and prolonged immunological effects. In the repeated-dose toxicity study in SD rats, LY01620 exhibited a favorable safety profile, with the no observed adverse effect level was the highest dose of 300 μg/animal. In conclusion, preclinical studies have demonstrated that LY01620 exhibited favorable mechanism of action-related efficacy and a well-tolerated safety profile, supporting its further development.
SN - 1664-3224
ER -